To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.
Symptomatic paroxysmal or persistent atrial fibrillation
CHADS2-VASc score≥ 2
Conform to the diagnosis of HFpEF
NYHA II-IV level;
A life expectancy below 2 years due to any non-cardiovascular condition
Reversible atrial fibrillation, such as hyperthyroidism or hypokalemia-related atrial fibrillation
Prior atrial fibrillation ablation
Left atrial size≥ 55 mm
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor